Cite
HARVARD Citation
Kremsner, P. et al. (2022). Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial. Lancet infectious diseases. 22 (3), pp. 329-340. [Online].